HIT Consultant September 5, 2024
What You Should Know:
– Genetic Leap, a pioneering AI-native techbio company, has entered into a strategic research collaboration with Eli Lilly and Company.
– The partnership aims to develop innovative genetic medicine therapeutics using Genetic Leap’s cutting-edge RNA-targeted AI platform.
Leveraging AI to Revolutionize RNA Drug Discovery
RNA genetic medicine holds immense promise for addressing a wide range of diseases. By targeting RNA, scientists can potentially develop therapies for conditions such as cancer, genetic disorders, and infectious diseases.
RNA plays a crucial role in regulating gene expression and protein production. By targeting RNA, scientists can potentially develop new therapies for diseases that have been difficult to treat with traditional drugs. However, drugging RNA has presented significant challenges...
Today's Sponsors
Today's Sponsor